Cannabis use disorder

What research says

Prevalence. Estimates range from 1-3 percent lifetime for CUD in the US, though rates have risen with legalization. Regular use rates have risen substantially. NIDA and NIAAA-supported surveys (NSDUH, NESARC) track trends.

Course. Variable. Some patients have transient use patterns that resolve. Others develop chronic dependence with substantial functional impairment.

Cannabis-induced psychotic disorder. Real and diagnosed. Typically resolves with abstinence but may recur with resumed use. In some patients with underlying vulnerability, cannabis-induced psychosis appears to unmask or accelerate onset of a persistent psychotic disorder.

Long-term outcomes. Meta-analyses (particularly the work of Marconi and colleagues 2016) show that cannabis use is associated with elevated risk of psychosis, with higher potency and more frequent use showing stronger associations. Di Forti's EU-GEI study (2019 Lancet Psychiatry) demonstrated that daily use of high-potency cannabis was associated with substantial elevated risk of first-episode psychosis compared to non-users.

Cannabinoid hyperemesis syndrome (CHS). Increasingly recognized. Case reports first published in 2004; now widely reported. Treatment is cannabis cessation.

Treatment research.

• Cognitive-behavioral therapy has evidence from multiple trials
• Motivational enhancement therapy has evidence
• Contingency management (financial incentives for negative drug screens) has evidence from multiple studies
• The combination of CBT plus MET plus contingency management has the best evidence (multiple trials in the 2000s-2010s)
• N-acetylcysteine (NAC) has small trial evidence with mixed results
• No medication is FDA-approved for CUD

Comorbidity. - Depression, anxiety, and other mood disorders in a substantial minority - Other substance use disorders - ADHD - PTSD - Schizophrenia-spectrum disorders in a subset - Chronic pain

What CUD is

Under DSM-5-TR, CUD is diagnosed when a person shows a problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by at least two of eleven criteria within a 12-month period:

1. Cannabis taken in larger amounts or over a longer period than intended 2. Persistent desire or unsuccessful efforts to cut down or control use 3. Great deal of time spent obtaining, using, or recovering from effects 4. Craving or a strong desire to use cannabis 5. Recurrent use resulting in failure to fulfill major role obligations 6. Continued use despite persistent or recurrent social or interpersonal problems 7. Important activities given up or reduced 8. Recurrent use in situations that are physically hazardous 9. Continued use despite knowledge of persistent physical or psychological problems caused or worsened 10. Tolerance 11. Withdrawal (which was added as a formal criterion in DSM-5, reflecting the recognized cannabis withdrawal syndrome)

Severity: mild (2-3 criteria), moderate (4-5), severe (6 or more).

Cannabis withdrawal syndrome (recognized in DSM-5 and DSM-5-TR): occurs after cessation of prolonged heavy cannabis use, typically within 24-72 hours, and can include irritability, anger, aggression, nervousness, anxiety, sleep difficulty (often with vivid dreams), decreased appetite, restlessness, depressed mood, and physical symptoms (abdominal pain, tremor, sweating, fever, chills, headache). Duration is typically 1-2 weeks, though sleep disturbance and mood changes can persist longer.

ICD-11 uses similar clinical concepts under "cannabis dependence."

The picture has changed

Understanding CUD in current context requires understanding how cannabis itself has changed.

Potency. Average THC content in commercial cannabis products has risen dramatically. In the 1990s, seized cannabis samples typically contained 3-5% THC. Current commercial flower typically contains 15-25% THC, and concentrates (dabs, wax, shatter, distillates) contain 60-90%+. Vape cartridges commonly contain 70-90% THC. Edibles are dosed in discrete milligrams of THC and vary widely.

Product diversity. Beyond smoked flower, current products include: - Concentrates for dabbing or vaporization - Vape cartridges - Edibles (gummies, chocolates, beverages, baked goods) - Tinctures and oils for sublingual use - Topicals (not psychoactive) - Cannabinoid-specific products (high-CBD, THCA, delta-8-THC, etc.)

Delta-8-THC and other cannabinoid analogs. The 2018 Farm Bill's language around hemp-derived cannabinoids created a market for delta-8, delta-10, and other analogs sold in states where delta-9-THC remains restricted. Regulatory oversight is limited; product quality and dose accuracy vary widely.

Legalization. As of 2026, most US states permit medical cannabis and many permit adult recreational use. Federal law still classifies cannabis as Schedule I. The legal-regulatory context varies enormously by state and continues to evolve.

Medical use is common for pain, nausea, anxiety, insomnia, and other indications. Evidence for medical benefit varies substantially by indication: reasonably good evidence for chemotherapy-induced nausea, cachexia in HIV/AIDS, and some pain conditions; more limited or contested evidence for anxiety, insomnia, and PTSD.

Implications for CUD. Higher potency, more varied products, wider availability, and reduced legal risk have shifted the landscape in ways that: - Elevate risk of adverse effects, particularly acute psychosis and CHS - Complicate assessment (patients often don't know the potency of products they use) - Make comparisons to older cannabis research (based on lower-potency flower) less directly applicable - Increase the population at risk for CUD without decreasing the medical or research need for effective treatment

What it feels like

The internal experience varies substantially depending on the product, dose, pattern of use, and individual.

Acute effects. Euphoria, relaxation, altered perception of time, altered sensory experience, hunger, and sometimes anxiety or paranoia. At higher doses (particularly with concentrates, edibles, or in non-tolerant users), acute effects can include intense anxiety, panic attacks, dissociation (depersonalization or derealization), acute psychotic experiences, and rarely vomiting.

Tolerance. With regular use, the person needs more to achieve similar effects. Tolerance develops within days to weeks of regular use. Cross-tolerance between different cannabis products is variable; a person tolerant to smoked flower may still be affected by high-potency concentrates in ways they don't expect.

Withdrawal. When cannabis is stopped after regular heavy use, characteristic withdrawal symptoms emerge. The person may find that their sleep is disrupted with vivid or unpleasant dreams, appetite is decreased, they feel irritable or on edge, and mood is low. These typically peak in the first week and gradually resolve, though sleep effects can persist longer. Many patients don't recognize these as withdrawal and interpret them as evidence they need cannabis.

Chronic use. Cannabis-related impairment often develops gradually and can be difficult to recognize. Common patterns: - Cognitive slowing during and immediately after use - Amotivation, particularly in heavy users - Reduced participation in previously valued activities - Sleep dependence (unable to sleep without cannabis) - Persistent low-grade anxiety or mood alterations that improve with abstinence - Concentration difficulty - The felt sense that cannabis has become necessary for functioning

Cravings. Persistent desire to use, triggered by environmental cues, emotional states, and internal drives.

Recognition of the problem is often gradual. The person may not initially recognize the effects. Others (family, employers, doctors) may notice before the person does.

Differential diagnosis and diagnostic considerations

Cannabis use without CUD. Occasional or moderate use without impairment doesn't meet criteria.

Anxiety disorders. Cannabis is often used to manage anxiety; some anxiety symptoms remit with cessation, while others become clearer once cannabis effects are removed. Careful sequencing of assessment often matters.

Depression. Depression and cannabis use frequently co-occur. Cannabis may be used to manage depressive symptoms; heavy use may worsen depression. Distinguishing primary depression from cannabis-related mood changes may require a period of abstinence.

Psychotic disorders. Cannabis-induced psychotic disorder resolves with abstinence. A first-episode of schizophrenia triggered or unmasked by cannabis persists after abstinence. Distinguishing these often requires longitudinal follow-up.

Depersonalization-derealization disorder. Cannabis is a common trigger. Assessment considers whether DPDR persists beyond acute use.

Cannabinoid hyperemesis syndrome. Cyclic vomiting relieved by hot showers in a chronic cannabis user should prompt consideration of CHS.

Other substance use disorders. Polysubstance use is common. Assessment considers each substance.

Why it happens

Neurobiology. THC is the primary psychoactive component; it acts on the endocannabinoid system through CB1 receptors. Effects on the mesolimbic dopamine system produce reinforcement. Chronic use produces adaptations in the endocannabinoid system that maintain use and produce withdrawal on cessation. CBD (cannabidiol), another cannabinoid, has different pharmacological effects and may modulate some of THC's effects; ratios of THC to CBD in modern products often favor THC substantially over historical levels.

Genetics. Substance use disorders including CUD show substantial heritability, with estimates in the 40-50 percent range. Multiple genes contribute.

Environmental factors. - Adolescent onset elevates CUD risk substantially (studies suggest cannabis use starting before age 18 approximately doubles CUD risk compared to adult-onset use) - Availability and social acceptance - Trauma exposure - Untreated psychiatric conditions (anxiety, depression, PTSD, ADHD) - Family and peer patterns of use - Chronic pain

Adolescent brain considerations. The adolescent brain is still developing, particularly in prefrontal regions involved in decision-making and impulse control. Cannabis exposure during adolescence has been associated in some studies with structural and functional differences and with elevated risk of psychosis, cognitive changes, and CUD, though the causal picture remains actively researched. Concerns about adolescent use are well-founded even amid overall shifting attitudes.

Assessment

Clinical interview covering the DSM-5-TR criteria. Assessment should also include:

• Products used (flower, concentrates, vape carts, edibles, delta-8, other cannabinoids)
• Route of administration
• Frequency and typical dose
• Age at first use and pattern of use over time
• Medical vs recreational context
• Withdrawal symptoms on cessation attempts
• Prior treatment attempts and outcomes
• Psychiatric comorbidities
• History of psychotic experiences (transient or persistent)
• History of cyclic vomiting (CHS screening)
• Function and impairment
• Motivation for change

Urine drug screen: THC-COOH is detectable for weeks after heavy use, which can be useful for monitoring but is also a barrier to some employment and legal contexts.

Treatment

The evidence base is limited compared to alcohol and opioid use disorders. No FDA-approved medication.

Psychosocial treatment.

• Cognitive-behavioral therapy targeting the specific patterns of cannabis use, triggers, and beliefs. Typical courses run 8-16 sessions.
• Motivational enhancement therapy (or motivational interviewing) helps engage patients who are ambivalent about change. Often combined with CBT.
• Contingency management provides tangible rewards (vouchers, prize draws) for negative drug screens. Evidence base is strong; implementation is limited by cost and structural factors.
• Mindfulness-based relapse prevention has some evidence.
• Family therapy for adolescent CUD has evidence.

The combination of CBT + MET + contingency management produces the best outcomes in trials.

Medication.

• No FDA-approved medication for CUD
• Medications with small-trial evidence with mixed results:
• N-acetylcysteine (NAC): 1200 mg twice daily
• Gabapentin
• Certain antidepressants for co-occurring depression
• Not evidence-based: SSRIs alone for CUD, benzodiazepines
• Treatment of co-occurring psychiatric conditions with standard evidence-based treatment often helps CUD outcomes indirectly

Managing cannabis withdrawal. For heavy users stopping abruptly: - Reassurance that withdrawal is time-limited (typically peaks in first week, largely resolves by 2 weeks) - Sleep hygiene support (sleep disturbance is often the most persistent symptom) - Managing mood and irritability - Symptomatic support (attention to appetite, hydration) - In some cases, tapered reduction rather than abrupt cessation

Harm reduction for patients not ready to stop.

• Reducing potency (lower-THC products)
• Reducing frequency
• Avoiding higher-risk products and routes (concentrates, dabbing)
• Not driving under the influence
• Avoiding cannabis during pregnancy
• Recognizing signs of CHS
• Not using in adolescents

Treatment of co-occurring conditions. Anxiety, depression, PTSD, and ADHD often accompany CUD and need direct attention. Some patients experience substantial improvement in cannabis use when the underlying condition is treated effectively.

Special populations.

• Adolescents: family-based treatment approaches have better evidence than adult approaches
• Pregnant patients: cannabis use is associated with adverse pregnancy outcomes; cessation is recommended, and if that's not achievable, harm reduction and close monitoring
• Patients with psychotic-spectrum disorders: cessation is strongly recommended given the elevated risk

Common comorbidities in detail

Depression is very common. Cannabis may be used to manage depressive symptoms; heavy use may worsen depression. Standard depression treatment applies.

Anxiety disorders are very common. Complex relationship: cannabis may reduce anxiety acutely but worsen it in the long run. Many patients find their anxiety improves with cessation, though the initial period of withdrawal may be difficult.

PTSD is common. Cannabis is often used for symptom management, particularly for sleep and hyperarousal. Evidence for medical cannabis in PTSD is mixed; some patients report symptom relief but risk of CUD is elevated.

ADHD shows some association with CUD. Untreated ADHD elevates CUD risk; treated ADHD may reduce it. Stimulant medication for ADHD in patients with concurrent CUD requires careful management.

Schizophrenia-spectrum disorders in a subset. Cannabis worsens the illness and complicates treatment. Cessation is strongly recommended.

Other substance use disorders frequently co-occur. Integrated treatment is often more effective than sequential treatment.

Chronic pain may be one of the drivers of use. Adequate pain management alongside CUD treatment matters.

Cannabinoid hyperemesis syndrome is a medical consequence of heavy chronic use. Resolves with cessation.

Cognitive changes. Chronic heavy use has been associated with cognitive changes, particularly in memory and attention. The extent of persistence after cessation and the effects specifically of use starting in adolescence remain areas of active research.

Cultural and structural considerations

Legalization variation. Cannabis remains illegal at the federal level and in some states, legal for medical use in most states, and legal for adult recreational use in many. The legal-regulatory context has changed rapidly and continues to change. Patients face very different circumstances depending on state.

Racial disparities in enforcement. Cannabis arrests and convictions have historically disproportionately affected Black and Hispanic Americans despite similar rates of use across racial groups. Consequences of these disparities persist even in states with recreational legalization.

Medical use vs recreational use. The distinction matters for individual patients but the underlying pharmacology is similar. Framing of use affects assessment and treatment engagement.

Adolescent use. Access to legal cannabis has generally increased with legalization; enforcement of age restrictions varies. Adolescent-onset use elevates CUD risk substantially.

Immigrant and refugee populations may face specific concerns around cannabis use given differences in legal frameworks and cultural attitudes across countries.

Living with CUD

For the person. Recognizing the pattern is often the hardest step. Many patients discover in retrospect that their cannabis use had been affecting their function more than they realized. Cessation is often followed by initial worsening of sleep, mood, and anxiety before improvement; understanding this in advance helps sustain the initial phase. Support - through a therapist, family, or peer support - typically helps. Treatment of co-occurring conditions often produces the biggest gains.

For family or partners. Understanding CUD as a chronic condition rather than a moral failing reduces conflict. Setting limits based on your own needs is legitimate. Encouraging engagement with treatment is often the most useful thing family can do. Not enabling continued use (through providing money for cannabis, minimizing consequences, or covering for the person) tends to help; being overtly punitive typically doesn't. Individual support for you matters.